Q1 2017 Titan Pharmaceuticals Inc Earnings Call

10/5/2017 16:15

Llamada en conferencia Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc Conference call or earnings call will be held on 10-may-2017 During the earnings conference call's session Titan Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Titan Pharmaceuticals Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Our product development programs utilize our proprietary long-term drug delivery platform, ProNeura®, and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. All share and per share amounts give retroactive effect to a 1 for 5.5 reverse stock split effected in September 2015. Probuphine®, our first product candidate to utilize ProNeura, is being developed for the long term maintenance treatment of opioid dependence and is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment. We have licensed the rights to commercialize Probuphine in the U.S. and Canada to Braeburn Pharmaceuticals, Inc.    
Leer más Llamada en conferencia

Titan Pharmaceuticals Inc (TTNP)

400 Oyster Point Boulevard, South San Francisco California 94080, United States